Assessing cost-effectiveness of HPV vaccines with decision analytic models: what are the distinct challenges of low- and middle-income countries? A protocol for a systematic review

被引:4
|
作者
Ekwunife O.I. [1 ,2 ]
Grote A.G. [3 ]
Mosch C. [4 ]
O'Mahony J.F. [5 ]
Lhachimi S.K. [1 ,6 ]
机构
[1] Leibniz Institute for Prevention Research and Epidemiology-BIPS, Cooperative Research Group for Evidence-Based Public Health, Department of Prevention and Evaluation, Bremen
[2] Nnamdi Azikiwe University, Department of Clinical Pharmacy and Pharmacy Management, Awka
[3] Institute for Quality and Efficiency in Health Care (IQWiG), Cologne
[4] Institute for Research in Operative Medicine (IFOM), Universität Witten/Herdecke, Witten
[5] School of Medicine, Trinity College Dublin, Department of Health Policy and Management, Dublin
[6] Institute for Public Health and Nursing Research-IPP, Health Sciences Bremen, University of Bremen, Bremen
关键词
Cost-effectiveness analysis; Low- and middle-income countries; Mass vaccination; Papillomavirus vaccines; Uterine cervical neoplasm;
D O I
10.1186/s13643-015-0057-8
中图分类号
学科分类号
摘要
Background: Cervical cancer poses a huge health burden, both to developed and developing nations, making prevention and control strategies necessary. However, the challenges of designing and implementing prevention strategies differ for low- and middle-income countries (LMICs) as compared to countries with fully developed health care systems. Moreover, for many LMICs, much of the data needed for decision analytic modelling, such as prevalence, will most likely only be partly available or measured with much larger uncertainty. Lastly, imperfect implementation of human papillomavirus (HPV) vaccination may influence the effectiveness of cervical cancer prevention in unpredictable ways. This systematic review aims to assess how decision analytic modelling studies of HPV cost-effectiveness in LMICs accounted for the particular challenges faced in such countries. Specifically, the study will assess the following: (1) whether the existing literature on cost-effectiveness modelling of HPV vaccines acknowledges the distinct challenges of LMICs, (2) how these challenges were accommodated in the models, (3) whether certain parameters systemically exhibited large degrees of uncertainty due to lack of data and how influential were these parameters on model-based recommendations, and (4) whether the choice of modelling herd immunity influences model-based recommendations, especially when coverage of a HPV vaccination program is not optimal. Methods: We will conduct a systematic review to identify suitable studies from MEDLINE (via PubMed), EMBASE, NHS Economic Evaluation Database (NHS EED), EconLit, Web of Science, and CEA Registry. Searches will be conducted for studies of interest published since 2006. The searches will be supplemented by hand searching of the most relevant papers found in the search. Studies will be critically appraised using Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement checklist. We will undertake a descriptive, narrative, and interpretative synthesis of data to address the study objectives. Discussion: The proposed systematic review will assess how the cost-effectiveness studies of HPV vaccines accounted for the distinct challenges of LMICs. The gaps identified will expose areas for additional research as well as challenges that need to be accounted for in future modelling studies. Systematic review registration: PROSPERO CRD42015017870 . © 2015 Ekwunife et al.; licensee BioMed Central.
引用
收藏
相关论文
共 50 条
  • [31] The cost-effectiveness of preventing mother-to-child transmission of HIV in low- and middle-income countries: Systematic review
    Johri M.
    Ako-Arrey D.
    Cost Effectiveness and Resource Allocation, 9 (1)
  • [32] Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines
    A. T. Newall
    M. Jit
    R. Hutubessy
    PharmacoEconomics, 2014, 32 : 525 - 531
  • [33] Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines
    Newall, A. T.
    Jit, M.
    Hutubessy, R.
    PHARMACOECONOMICS, 2014, 32 (06) : 525 - 531
  • [34] Cost and cost-effectiveness of childhood cancer treatment in low-income and middle-income countries: a systematic review
    Fung, Alastair
    Horton, Susan
    Zabih, Veda
    Denburg, Avram
    Gupta, Sumit
    BMJ GLOBAL HEALTH, 2019, 4 (05):
  • [35] Cost-effectiveness analysis of interventions for migraine in four low- and middle-income countries
    Linde, Mattias
    Steiner, Timothy J.
    Chisholm, Dan
    JOURNAL OF HEADACHE AND PAIN, 2015, 16
  • [36] Cost-effectiveness of Coronavirus Disease 2019 Vaccination in Low- and Middle-Income Countries
    Siedner, Mark J.
    Alba, Christopher
    Fitzmaurice, Kieran P.
    Gilbert, Rebecca F.
    Scott, Justine A.
    Shebl, Fatma M.
    Ciaranello, Andrea
    Reddy, Krishna P.
    Freedberg, Kenneth A.
    JOURNAL OF INFECTIOUS DISEASES, 2022, 226 (11): : 1887 - 1896
  • [37] Cost-effectiveness analyses for injury prevention initiatives in low- and middle-income countries
    Scuffham, Paul A.
    INJURY PREVENTION, 2008, 14 (04) : 217 - 219
  • [38] The cost-effectiveness of hepatitis C virus elimination in low- and middle-income countries
    Razavi, Homie
    JOURNAL OF VIRAL HEPATITIS, 2021, 28 (02) : 445 - 445
  • [39] Ranking 93 health interventions for low- and middle-income countries by cost-effectiveness
    Horton, Susan
    Gelband, Hellen
    Jamison, Dean
    Levin, Carol
    Nugent, Rachel
    Watkins, David
    PLOS ONE, 2017, 12 (08):
  • [40] Cost-effectiveness analysis of interventions for migraine in four low- and middle-income countries
    Mattias Linde
    Timothy J Steiner
    Dan Chisholm
    The Journal of Headache and Pain, 2015, 16